Tag: Biosimilars
Biocon reports 30% revenue increase and ₹660 crore net profit in...
Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success
Zydus Lifesciences secures COFEPRIS approval to market MamitraTM in Mexico for...
With the approval of MamitraTM, Zydus aims to provide affordable cancer treatments for HER2-positive breast and gastric cancer patients
EMA approves Biocon Biologics’ new mAbs facility in India
European Medicines Agency also renews GMP certifications for Biocon's manufacturing sites in India and Malaysia, enhancing global biosimilars supply
Biocon’s biosimilars revenue crosses milestone of US $1 Billion in FY...
The company garnered an overall revenue of Rs 15,621 Crore in FY24, marking a remarkable 35% growth compared to the previous year
“Popularity of biosimilars will continue to rise, attracting more interest &...
Ravikrishna Chebolu, General Manager, India, West Pharmaceutical Services, Inc. talks about company’s product offerings, latest activities, market trends, unique strategies and future outlook.
Biocon Biologics partners Sandoz Australia for sale of biosimilars, Trastuzumab &...
The agreement is effective from January 1, 2024 and commercialization commenced on February 1, 2024
Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...
The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore
Biocon Biologics concludes integration of acquired biosimilars business in 120 countries
Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris.
Biocon Biologics successfully completes integration of Viatris’ biosimilar business in 31...
In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept
Biocon Biologics announces divestment of two non-core branded formulations business units
The move is in line with the company’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company